Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | AR | P10275 | 2/20 | 0.73 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.73 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887054 | 1.00 | MAOB (1.00) | MAOBNPC1MAPTRAB9ACYP19A1 | |
| SCHEMBL11252779 | 0.86 | MAOB (0.76) | MAOBNPC1MAPTRAB9ACYP19A1 | |
| SCHEMBL31562151 | 0.86 | MAOB (0.76) | MAOBNPC1MAPTRAB9ACYP19A1 | |
| Liquiritigenin Dimethyl Ether SCHEMBL3303937 | 0.86 | CYP19A1 (1.00) | MAOBNPC1MAPTRAB9ACYP19A1 | |
| SCHEMBL22680315 | 0.86 | ABCB1 (0.87) | MAOBNPC1MAPTRAB9ACYP19A1 | |
| Liquiritigenin Dimethyl Ether SCHEMBL13394438 | 0.86 | CYP19A1 (1.00) | MAOBNPC1MAPTRAB9ACYP19A1 | |
| SCHEMBL25437506 | 0.85 | MAOB (0.74) | MAOBNPC1MAPTRAB9ACYP19A1 | |
| Flavanone SCHEMBL19745 | 0.85 | MAOB (1.00) | MAOBNPC1MAPTRAB9ACYP19A1 | |
| Flavanone SCHEMBL12189591 | 0.85 | MAOB (1.00) | MAOBNPC1MAPTRAB9ACYP19A1 | |
| Flavanone SCHEMBL29843289 | 0.85 | MAOB (1.00) | MAOBNPC1MAPTRAB9ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025091065-A1 | FLAVONOID COMPOSITION | GRETALS AUSTRALIA PTY LTD (AU) | 2025-05-08 | — | — | WO | claimed |
| US-20230172901-A1 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS | GRETALS AUSTRALIA PTY LTD (AU) | 2023-06-08 | — | — | US | claimed |
| EP-4146194-A1 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS | Gretals Australia Pty Ltd (AU) | 2023-03-15 | — | — | EP | claimed |
| WO-2021222987-A1 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS | GRETALS AUSTRALIA PTY LTD (AU) | 2021-11-11 | — | — | WO | claimed |
| EP-1764363-A2 | SUBSTITUTED ACETOPHENONEDERIVATIVES | Riemser Arzneimittel AG (DE) | 2007-03-21 | — | — | EP | claimed |
| US-20260033492-A1 | Pest Repellents and Uses Thereof | SENSORYGEN INC (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025091065-A1 | FLAVONOID COMPOSITION | GRETALS AUSTRALIA PTY LTD (AU) | 2025-05-08 | — | — | WO | disclosed |
| US-12280129-B2 | Compositions and methods for improved skin care | PINSKY MARK A (US) | 2025-04-22 | — | — | US | disclosed |
| CN-117761174-A | Method for detecting metabolites in konjak and rhizosphere soil at different Pcc infection stages | 昆明学院 | 2024-03-26 | — | — | CN | disclosed |
| EP-4307910-A1 | FLAVORED FIBER BLENDS AND THEIR COMESTIBLE USE | Firmenich SA (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-20230292754-A1 | Pest Repellents and Uses Thereof | UNIVERSITY OF CALIFORNIA RIVERSIDE | 2023-09-21 | — | — | US | disclosed |
| EP-4228408-A1 | PEST REPELLENTS AND USES THEREOF | Sensorygen, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-6093411-A | AN EMULSION COMPRISING FLAVONOIDS FOR PREVENTING OR TREATING SKIN DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| US-6051602-A | METHODS FOR PREVENTION OR TREATING SKIN DISORDERS USING FLAVONOID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2000-04-18 | — | — | US | disclosed |
| WO-1999047118-A1 | COMPOSITIONS FOR REGULATING SKIN APPEARANCE | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999047113-A1 | COMPOSITIONS FOR REGULATING SKIN APPEARANCE | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999047119-A1 | METHODS FOR REGULATING SKIN APPEARANCE | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| EP-0025161-B1 | 3-METHYLENE FLAVANONES AND 3-METHYLENE CHROMANONES, ANTIMICROBIAL COMPOSITION CONTAINING SAME AND METHOD OF INHIBITING THE GROWTH OF MICROORGANISMS | MILES LABORATORIES, INC. (US) | 1982-06-09 | — | — | EP | disclosed |
| EP-0025161-A1 | 3-Methylene flavanones and 3-methylene chromanones, antimicrobial composition containing same and method of inhibiting the growth of microorganisms | MILES LABORATORIES, INC. (US) | 1981-03-18 | — | — | EP | disclosed |
| US-4241069-A | MICROBIOCIDES | MILES LABORATORIES, INC. (US) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260033492-A1 | Pest Repellents and Uses Thereof | F3, TFPI, FLI1 | MAOB 1790/4885NPC1 1031/4885MAPT 122/4885 |
| US-20230172901-A1 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS | MMP1, COL1A1, SERPINB1 | MAOB 2184/4885NPC1 1063/4885MAPT 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.